Cingulate Inc. operates as a clinical stage biopharmaceutical company. The Company develops pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.

Current Report (Form 8-K | Period ending 2024-08-28)

424B3 | Prospectus

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Cingulate (CING US)

Current Report (Form 8-K | Period ending 2024-08-28)

424B3 | Prospectus

S-1 | IPO Registration

Current Report (Form 8-K | Period ending 2024-08-15)

424B5 | Prospectus

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)